Interaction of Warfarin with Herbs Based on Pharmacokinetic and Pharmacodynamic Parameters

Amelia Soyata, Aliya Nur Hasanah, Taofik Rusdiana

Abstract

Warfarin is an oral anticoagulant that has been widely used and has strong efficacy, but the use of warfarin is still a concern because of its narrow therapeutic index which cause interactions when co-administration with drugs, herbs or food. This interaction can affect the pharmacokinetics and pharmacodynamics of warfarin and the most fatal effect from warfarin interactions is bleeding. In this review article data on warfarin-herbs interactions were collected based on pharmacokinetic parameters (AUC0-∞, Cmax, T1/2, Cl/F, and V/F), while pharmacodynamic parameters (International normalized ratio (INR), platelet aggregation, AUC INR and Protombine Time). As a result some herbs had significant interactions with warfarin. Herbs that affect warfarin pharmacokinetic were Danshen gegen, echinacea, St. John's wort and caffeine and herbs that affect pharmacodynamic were policosanol, Ginkgo biloba, cranberry, St. John's wort, ginseng, pomegranate, Psidium guajava and curcumin, so co-administration warfarin with herbs need to be considered.

Keywords: Warfarin, Interactions, Herbs, Pharmacokinetics, Pharmacodynamics

Full Text:

PDF HTML

References

Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. 2008;(March):757–63.

Piatkov I, Rochester C, Jones T, Boyages S. Warfarin Toxicity and Individual Variability-Clinical Case. Toxins (Basel). 2010;2(11):2584–92.

Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5(4):262–70.

Varma M V, Pang SK, Isoherranen N, Zhao P. Dealing with the complex drug–drug interactions: Towards mechanistic models Manthena. Biopharm Drug Dispos. 2015;36:71–92.

Colet C, Amador TA, Heineck I. Drug Interactions and Adverse Events in a Cohort of Warfarin Users Attending Public Health Clinics. Int J Cardiovasc Sci. 2019;32(2):110–7.

Ramsay NA, Kenny MW, Davies G, Patel JP. Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol. 2005;130(5):777–80.

Ernst E, Pittler M, STevinson C, White A. The Desktop Guide to Complementary and Alternative Medicine. J Clin Pharmacol. 2002;54:71.

Qiu F, Wang G, Zhao Y, Sun H, Mao G, A J, et al. Effect of danshen extract on pharmacokinetics of theophylline in healthy volunteers. Br J Clin Pharmacol. 2008;65(2):270–4.

Vieira MT, Huang S, Spring S. Botanical-Drug Interactions : A Scientific Perspective. 2012;1400–15.

Ngui JS, Chen Q, Shou M, Wang RW, Stearns RA, Baillie TA, et al. In vitro stimulation of warfarin metabolism by quinidine: Increases in the formation of 4′- and 10-hydroxywarfarin. Drug Metab Dispos. 2001;29(6):877–86.

Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007;121(1):23–34.

Zhang Z, Ge B, Zhou L, Lam TN, Zuo Z. Induction of liver cytochrome P450s by Danshen-Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin. J Ethnopharmacol [Internet]. 2014;154(3):672–86. Available from: http://dx.doi.org/10.1016/j.jep.2014.04.047

Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom. 2004;18(19):2273–81.

Guo LQ, Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin. 2004;25(2):129–36.

Yale SH, Glurich I. Analysis of the Inhibitory Potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the Metabolic Activity of Cytochrome P450 3A4, 2D6, and 2C9. J alernative Complement Med. 2005;11(3):433–9.

Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol. 2003;43(6):643–8.

Guo LQ, Taniguchi M, Chen QY, Baba K, Yamazoe Y. Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: Properties of Umbelliferous or Citrus crude drugs and their relative prescriptions. Jpn J Pharmacol. 2001;85(4):399–408.

Williamson E, Driver S, Baxter K. Herbal Medicines Interaction. USA: RPS Publishing; 2009. 432 p.

Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005;70(7):1096–103.

Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013;18(7):600–9.

Tirona RG, Kim RB. Introduction to Clinical Pharmacology. Clin Transl Sci Princ Hum Res Second Ed. 2017;365–88.

Tripathi MM, Egawa S, Wirth AG, Tshikudi DM, Van Cott EM, Nadkarni SK. Clinical evaluation of whole blood prothrombin time (PT) and international normalized ratio (INR) using a Laser Speckle Rheology sensor. Sci Rep [Internet]. 2017;7(1):1–8. Available from: http://dx.doi.org/10.1038/s41598-017-08693-5

Zhou L, Wang S, Zhang Z, San Lau B, Pui Fung K, Chung Leung P, et al. Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin. J Ethnopharmacol [Internet]. 2012;143(2):648–55. Available from: http://dx.doi.org/10.1016/j.jep.2012.07.029

Abdul MIM, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, et al. Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol. 2010;69(5):508–15.

Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59(4):425–32.

Abdul MM, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol. 2008;154(8):1691–700.

Jiang, X, Williams, K.M., Liauw WS. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2006;57(5):592–9.

Alnaqeeb M, Mansor KA, Idkaidek N, Qinna NA, Mallah EM, Ghanim BY. Critical pharmacokinetic and pharmacodynamic drug-herb interactions in rats between warfarin and pomegranate peel or guava leaves extracts. BMC Complement Altern Med. 2019;19(1):1–12.

Liu AC, Zhao LX, Lou HX. Curcumin alters the pharmacokinetics of warfarin and clopidogrel in wistar rats but has no effect on anticoagulation or antiplatelet aggregation. Planta Med. 2013;79(11):971–7.

Zafar S, Ali A, Ashraf MM, Khan JA, Aslam B, Naseer RD. Alteration in disposition kinetics of warfarin mediated by caffeine in healthy male albino rabbits. J Anim Plant Sci. 2019;29(1):158–65.

Chang Q, Sun L, Zhao RH, Chow MSS, Zuo Z. Simultaneous determination of ten active components in traditional Chinese medicinal products containing both gegen (Pueraria iobata) and danshen (Salvia miltiorrhiza) by high-performance liquid chromatography. Phytochem Anal. 2008;19(4):368–75.

Qin CZ, Ren X, Zhou HH, Mao XY, Liu ZQ. Inhibitory effect of salvianolate on human cytochrome P450 3A4 in vitro involving a noncompetitive manner. Int J Clin Exp Med. 2015;8(9):15549–55.

Wang BQ. Salvia miltiorrhiza chemical and pharmacological review of a medicinal plant. J Med Plants Res. 2010;4(25):2813–20.

Lin Y-L, Don M-J, Kuo Y-H, Chen R-M, Ueng Y-F. Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza . J Pharm Pharmacol. 2006;58(4):521–7.

Ueng YF, Kuo YH, Peng HC, Chen TL, Jan WC, Guengerich FP, et al. Diterpene quinone tanshinone IIA selectively inhibits mouse and human cytochrome P4501A2. Xenobiotica. 2003;33(6):603–13.

Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species ( Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties . J Pharm Pharmacol. 2005;57(8):929–54.

Irmak S, Dunford NT, Milligan J. Policosanol contents of beeswax, sugar cane and wheat extracts. Food Chem. 2006;95(2):312–8.

Gouni-Berthold I, Berthold HK. Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J. 2002;143(2):356–65.

Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75(1):89–100.

Castano G, Mas R, Fernandes L, Illnait J, Games R, Alvarez E. Effects of policosanol 20 versus 40 mg / day in the treatment of patients with type II hypercholesterolemia : a 6-month. Int J Clin Pharmacol Res. 2001;21(1):43–57.

Reiner Ž, Tedeschi-Reiner E. Rice policosanol does not have any effects on blood coagulation factors in hypercholesterolemic patients. Coll Antropol. 2007;31(4):1061–4.

Hummel MA, Locuson CW, Gannett PM, Rock DA, Mosher CM, Rettie AE, et al. CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: Switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol. 2005;68(3):644–51.

Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS. CYP2C9 inhibition: Impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos. 2006;34(12):1966–75.

Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients . A randomised, double blind , placebo-crossover trial variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002;87(6):1075–6.

Ohnishi N, Kusuhara M, Yoshioka M, Kuroda K, Soga A, Nishikawa F, et al. Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull. 2003;26(9):1315–20.

Sollier BD, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol. 2003;25(4):251–3.

Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci [Internet]. 2002;71(13):1579–89. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12127912

Nash KM, Shah ZA. Current perspectives on the beneficial role of Ginkgo biloba in neurological and cerebrovascular disorders. Integr Med Insights. 2015;10:1–9.

Umegaki K, Shinozuka K, Watarai K, Takenaka H, Yoshimura M, Daohua P, et al. Ginkgo biloba extract attenuates the development of hypertension in deoxycorticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol. 2000;27(4):277–82.

Greenblatt DJ, Von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies. Clin Pharmacol Ther. 2006;79(1):125–33.

Lilja JJ, Backman JT, Neuvonen PJ. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam - Probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther. 2007;81(6):833–9.

Li Z, Seeram NP, Carpenter CL, Thames G, Minutti C, Bowerman S. Cranberry Does Not Affect Prothrombin Time in Male Subjects on Warfarin. J Am Diet Assoc. 2006;106(12):2057–61.

Ansell J, McDonough M, Harmatz JS, Greenblatt DJ. A randomized, double-blind trial of the interaction between cranberry juice and warfarin. J Thromb Thrombolysis. 2008;25(1):112–112.

Hamann GL, Campbell JD, George CM. Warfarin-cranberry juice interaction. Ann Pharmacother. 2011;45(3).

Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine. 2000;7(4):273–82.

Wang Z, Christopher J. The Effect of St John’s Wort (Hypericum perforatum) on Human Cytochrome P450 Activity. Clin Pharmacol Ther. 2001;

Robertson GR, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, et al. Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol. 2003;64(1):42–50.

Mattiello T, Trifirò E, Jotti GS, Pulcinelli FM. Effects of pomegranate juice and extract polyphenols on platelet function. J Med Food. 2009;12(2):334–9.

Mozzicafreddo M, Cuccioloni M, Eleuteri AM, Fioretti E, Angeletti M. Flavonoids inhibit the amidolytic activity of human thrombin. Biochimie. 2006;88(9):1297–306.

Athukuri BL, Neerati P. Enhanced Oral Bioavailability of Diltiazem by the Influence of Gallic Acid and Ellagic Acid in Male Wistar Rats: Involvement of CYP3A and P-gp Inhibition. Phyther Res. 2017;31(9):1441–8.

Kaneko K, Suzuki K, Iwadate-Iwata E, Kato I, Uchida K, Onoue M. Evaluation of food-drug interaction of guava leaf tea. Phyther Res. 2013;27(2):299–305.

Si D, Wang Y, Zhou YH, Guo Y, Wang J, Zhou H, et al. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos. 2009;37(3):629–34.

Kim DC, Lee W, Bae JS. Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro. Inflamm Res. 2011;60(12):1161–8.

Li Y, Revalde JL, Reid G, Paxton JW. Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol. 2011;68(3):603–10.

Shuaib W, Iftikhar H, Alweis R, Shahid H. Warfarin Therapy : Survey of Patients ’ Knowledge of their Drug Regimen. 2014;21(4):37–41.

DOI: https://doi.org/10.24198/idjp.v2i2.27289

Refbacks

  • There are currently no refbacks.